Sign inJoin waitlistJoin the waitlist

Joseph Lucci

Director, Division of Gynecologic Oncology · University of Texas Health Science Center at Houston

Credentials: · · · · ·

History

Sr. Program Manager · University of Texas Health Science Center at Houston
Present
University of Texas Health Science Center at Houston
Present
University of Texas Medical Branch Hospitals
Present

Gynecologic Oncology
University of California
1991–1994
Christus St. Joseph Hospital
1987–1991
McGovern Medical School at The University of Texas Health Science Center at Houston
1980–1984

Research

Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human…
Proceedings of the National Academy of Sciences of the United States of America · 1990 · 190 citations
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial
Cancer Chemotherapy and Pharmacology · 2003 · 160 citations
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients
Journal of Clinical Oncology · 2008 · 157 citations

EH
Edward Hannigan
9 papers
PD
Philip J Disaia
8 papers
AM
Alberto Manetta
7 papers
Anil Sood
7 papers
KG
Koen De Geest
7 papers
Fiona Simpkins
5 papers · 1 as a fellow
LM
Luis Mendez
5 papers
Michael Goodheart
5 papers · 1 as a fellow
MB
Michael L Berman
5 papers
Premal Thaker
5 papers
Samer Schuman
5 papers · 5 as a fellow
Bradley Monk
4 papers

Clinical trials

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia
Principal investigator · Withdrawn · Phase 2
The University of Texas Health Science Center, Houston
2018–2022
Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
Study chair · Withdrawn · Phase 1, Phase 2
University of Miami
2003–2009
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2022–2026